This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens.
-- Kimberly Smith, M.D., M.P.H.
In an interview on behalf of IFARA at CROI 2017, Fred Schaich spoke with Kimberly Smith about the potential for treating HIV with only two instead of three antiretrovirals. The goal here is to develop effective drugs with the fewest side effects.
The two SWORD studies presented at CROI randomized virally suppressed participants to continue their three- or four-drug treatment regimen or to switch to a new regimen consisting of dolutegravir (Tivicay, DTG) plus rilpivirine (Edurant). HIV levels remained undetectable in 95% of those in either study arm, proving that a two-drug regimen can be as effective as one with more medications.
Over 20% of enrollees in these trials were women and more than 25% were over 50 years old. Researchers wanted the study population to represent the demographic characteristics of those living with HIV, Smith noted.
Watch the video to learn more:
About the panelist:
Kimberly Smith, M.D., M.P.H., ViiV Healthcare.
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.
More Like This
Study Bite: DTG Not Associated With Neural Tube Defects in U.S.
Study Bite: Dolutegravir Safe, Effective Postpartum When Started During Pregnancy
Study Bite: Dolutegravir Uptake Low Among Young Women in South Africa
This Week in HIV Research: Weights and Measures
